NCT07001475 - A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

April 27, 2026

Study Completion Date

May 27, 2026

Conditions

Borderline Personality DisorderAttention Deficit Hyperactivity Disorder

Interventions

DRUG

BI 3031185

DRUG

Placebo

Placebo matching BI 3031185

Trial Locations (8)

RECRUITING

Charité Research Organisation GmbH, Berlin

RECRUITING

Universitätsklinikum Bonn AöR, Bonn

NOT_YET_RECRUITING

Rheinhessen-Fachklinik Mainz, Mainz

NOT_YET_RECRUITING

Universitätsklinikum Frankfurt, Frankfurt am Main

RECRUITING

Zentralinstitut für seelische Gesundheit, Mannheim

RECRUITING

Universitätsklinikum Tübingen, Tübingen

NOT_YET_RECRUITING

Martin-Luther-Universität Halle-Wittenberg, Halle

NOT_YET_RECRUITING

Universitätsklinikum Jena, Jena